TrialBMC cancer2019
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Florian Eichhorn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
43 papers cite it
this paperpooled ittrialcites it